等待开盘 09-24 09:30:00 美东时间
-1.820
-3.98%
Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and licensing partner Roche Holdings AG (OTC:RHHBY) on Wednesday shared prespecified interim outcomes from their ongoing Phase 3 IMAgINATION trial of investigational sefaxersen in adults diagnosed with primary IgA nephropathy (IgAN). "These interim phase 3 re...
09-23 20:13
今日重点评级关注:Citizens:上调Quince Therapeutics评级至"跑赢大市",目标价77美元;康托·菲茨杰拉德:维持塞德斯医疗"超配"评级,目标价从61美元升至72美元
09-23 15:30
当地时间9月22日,“木头姐”Cathie Wood旗下方舟投资(ARK Invest)公布的每日交易纪录显示,持股重心明显偏向大型AI平台与基因精准医疗,同时...
09-23 09:49
Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and Otsuka on Tuesday shared positive topline results from their Phase 3 FUSION trial. The trial evaluated ulefnersen, an investigational RNA-targeted medicine, in patients with amyotrophic lateral sclerosis (ALS) caused by mutations in the fused in sarcoma (...
09-23 00:11
Cathie Wood is doubling down on biotech, but investors looking beyond her ARK Genomic Revolution ETF (BATS:ARKG) have several other ways to gain exposure to the same companies. ARKG bought about $4.5 million of Ionis Pharmaceuticals Inc (NASDAQ:IONS), nearly $3 million of Veracyte Inc (NASDAQ:VCYT),...
09-22 22:40
Cathie Wood’s Ark Invest made several large portfolio moves last week, adding to CoreWeave (CRWV) while increasing exposure to healthcare and trimming positions across crypto, genomics and technology....
09-21 19:05
AI医疗概念周内狂飙!Tempus AI劲升32%,CEO释放长期增长指引;TWST升31%,与礼来TuneLab达成合作;FPS升24%,2027财年业绩指引大超预期>>
09-20 09:30
Novartis (NVS) has discontinued the development of VHB937/lifonebart, an experimental therapy for a fatal nervous system disease known as amyotrophic lateral sclerosis, following a mid-stage trial fai...
09-16 21:21
今日重点评级关注:HC Wainwright & Co.:上调Cardiff Oncology评级至"买入",目标价9美元;古根海姆:维持Inventiva"买入"评级,目标价从11美元升至14美元
09-16 16:10